Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment

International Immunology

Volumn 28, Issue 8, 2016, Pages 383-391

  Spranger, Stefani ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Checkpoint blockade; Immune evasion; Immunotherapy; Oncogenes

Indexed keywords

ADAPTIVE IMMUNITY; CELL INFILTRATION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; UPREGULATION; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; INFLAMMATION; NEOPLASM; PROCEDURES; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ESCAPE;

ADAPTIVE IMMUNITY; ANIMALS; HUMANS; IMMUNOTHERAPY; INFLAMMATION; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASMS; T-LYMPHOCYTES; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 84988976297     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxw014     Document Type: Review

References (73)

1. Hodi, F. S., O'Day, S. J., McDermott, D. F. et al. 2010. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363:711.
2. Topalian, S. L., Sznol, M., McDermott, D. F. et al. 2014. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol. 32:1020.
3. Topalian, S. L., Hodi, F. S., Brahmer, J. R. et al. 2012. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366:2443.
4. Larkin, J., Chiarion-Sileni, V., Gonzalez, R. et al. 2015. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373:23.
5. Tumeh, P. C., Harview, C. L., Yearley, J. H. et al. 2014. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515:568.
6. Galon, J., Costes, A., Sanchez-Cabo, F. et al. 2006. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960.
7. Ropponen, K. M., Eskelinen, M. J., Lipponen, P. K., Alhava, E. and Kosma, V. M. 1997. Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. J. Pathol. 182:318.
8. Naito, Y., Saito, K., Shiiba, K. et al. 1998. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 58:3491.
9. Harlin, H., Meng, Y., Peterson, A. C. et al. 2009. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res. 69:3077.
10. Salerno, E. P., Olson, W. C., McSkimming, C., Shea, S. and Slingluff, C. L. Jr 2014. T cells in the human metastatic melanoma microenvironment express site-specific homing receptors and retention integrins. Int. J. Cancer 134:563.
11. Spranger, S., Spaapen, R. M., Zha, Y. et al. 2013. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci. Transl. Med. 5:200ra116.
12. Hildner, K., Edelson, B. T., Purtha, W. E. et al. 2008. Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science 322:1097.
13. Engelhardt, J. J., Boldajipour, B., Beemiller, P. et al. 2012. Marginating dendritic cells of the tumor microenvironment crosspresent tumor antigens and stably engage tumor-specific T cells. Cancer Cell 21:402.
14. Fuertes, M. B., Kacha, A. K., Kline, J. et al. 2011. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells. J. Exp. Med. 208:2005.
15. Broz, M. L., Binnewies, M., Boldajipour, B. et al. 2014. Dissecting the tumor myeloid compartment reveals rare activating antigenpresenting cells critical for T cell immunity. Cancer Cell 26:638.
16. Woo, S. R., Fuertes, M. B., Corrales, L. et al. 2014. STINGdependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 41:830.
17. Corrales, L., Glickman, L. H., McWhirter, S. M. et al. 2015. Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. Cell Rep. 11:1018.
18. Snyder, A., Makarov, V., Merghoub, T. et al. 2014. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371:2189.
19. Rizvi, N. A., Hellmann, M. D., Snyder, A. et al. 2015. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348:124.
20. Gajewski, T., Zha, Y., Hernandez, K. et al. 2015. Density of immunogenic antigens and presence or absence of the T cell-inflamed tumor microenvironment in metastatic melanoma. J. Clin. Oncol. 33.
21. Mikucki, M. E., Fisher, D. T., Matsuzaki, J. et al. 2015. Nonredundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints. Nat. Commun. 6:7458.
22. Bedognetti, D., Spivey, T. L., Zhao, Y. et al. 2013. CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2. Br. J. Cancer 109:2412.
23. Spranger, S., Bao, R. Y. and Gajewski, T. F. 2015. Melanomaintrinsic beta-catenin signalling prevents anti-tumour immunity. Nature 523:231.
24. Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J. and Schreiber, R. D. 2002. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3:991.
25. DuPage, M., Cheung, A. F., Mazumdar, C. et al. 2011. Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression. Cancer Cell 19:72.
26. Munn, D. H., Zhou, M., Attwood, J. T. et al. 1998. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281:1191.
27. Gajewski, T. F. 2007. Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin. Cancer Res. 13(Pt 1):5256.
28. Yeung, O. W., Lo, C. M., Ling, C. C. et al. 2015. Alternatively activated (M2) macrophages promote tumour growth and invasiveness in hepatocellular carcinoma. J. Hepatol. 62:607.
29. Pandiyan, P., Zheng, L., Ishihara, S., Reed, J. and Lenardo, M. J. 2007. CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat. Immunol. 8:1353.
30. Read, S., Greenwald, R., Izcue, A. et al. 2006. Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo. J. Immunol. 177:4376.
31. Wing, K., Onishi, Y., Prieto-Martin, P. et al. 2008. CTLA-4 control over Foxp3+ regulatory T cell function. Science 322:271.
32. Kobie, J. J., Shah, P. R., Yang, L., Rebhahn, J. A., Fowell, D. J. and Mosmann, T. R. 2006. T regulatory and primed uncommitted CD4 T cells express CD73, which suppresses effector CD4 T cells by converting 5'-adenosine monophosphate to adenosine. J. Immunol. 177:6780.
33. Deaglio, S., Dwyer, K. M., Gao, W. et al. 2007. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med. 204:1257.
34. Bauer, C. A., Kim, E. Y., Marangoni, F. et al. 2014. Dynamic Treg interactions with intratumoral APCs promote local CTL dysfunction. J. Clin. Invest. 124:2425.
35. Marangoni, F., Murooka, T. T., Manzo, T. et al. 2013. The transcription factor NFAT exhibits signal memory during serial T cell interactions with antigen-presenting cells. Immunity 38:237.
36. Tadokoro, C. E., Shakhar, G., Shen, S. et al. 2006. Regulatory T cells inhibit stable contacts between CD4+ T cells and dendritic cells in vivo. J. Exp. Med. 203:505.
37. Taube, J. M., Anders, R. A., Young, G. D. et al. 2012. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci. Transl. Med. 4:127ra37.
38. Keir, M. E., Butte, M. J., Freeman, G. J. and Sharpe, A. H. 2008. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26:677.
39. Wherry, E. J. 2011. T cell exhaustion. Nat. Immunol. 12:492.
40. Freeman, G. J., Long, A. J., Iwai, Y. et al. 2000. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192:1027.
41. Baitsch, L., Baumgaertner, P., Devêvre, E. et al. 2011. Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients. J. Clin. Invest. 121:2350.
42. Gajewski, T. F., Schreiber, H. and Fu, Y. X. 2013. Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 14:1014.
43. Spranger, S., Koblish, H. K., Horton, B., Scherle, P. A., Newton, R. and Gajewski, T. F. 2014. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. J. Immunother. Cancer 2:3.
44. Postow, M. A., Chesney, J., Pavlick, A. C. et al. 2015. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 372:2006.
45. Curran, M. A., Kim, M., Montalvo, W., Al-Shamkhani, A. and Allison, J. P. 2011. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. PLoS One 6:e19499.
46. Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K. and Anderson, A. C. 2010. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 207:2187.
47. Matsushita, H., Vesely, M. D., Koboldt, D. C. et al. 2012. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482:400.
48. Schreiber, R. D., Old, L. J. and Smyth, M. J. 2011. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331:1565.
49. Gubin, M. M., Zhang, X., Schuster, H. et al. 2014. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515:577.
50. Bosenberg, M., Muthusamy, V., Curley, D. P. et al. 2006. Characterization of melanocyte-specific inducible Cre recombinase transgenic mice. Genesis 44:262.
51. Damsky, W. E., Curley, D. P., Santhanakrishnan, M. et al. 2011. β-catenin signaling controls metastasis in Braf-activated Ptendeficient melanomas. Cancer Cell 20:741.
52. Dankort, D., Curley, D. P., Cartlidge, R. A. et al. 2009. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat. Genet. 41:544.
53. Cheung, A. F., Dupage, M. J., Dong, H. K., Chen, J. and Jacks, T. 2008. Regulated expression of a tumor-associated antigen reveals multiple levels of T-cell tolerance in a mouse model of lung cancer. Cancer Res. 68:9459.
54. Peng, D., Kryczek, I., Nagarsheth, N. et al. 2015. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature 527:249.
55. Schmid, M. C., Avraamides, C. J., Dippold, H. C. et al. 2011. Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3k?, a single convergent point promoting tumor inflammation and progression. Cancer Cell. 19:715.
56. Coussens, L. M., Zitvogel, L. and Palucka, A. K. 2013. Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science 339:286.
57. Bronte, V. and Murray, P. J. 2015. Understanding local macrophage phenotypes in disease: modulating macrophage function to treat cancer. Nat. Med. 21:117.
58. Peng, W., Chen, J. Q., Liu, C. et al. 2016. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 6:202.
59. Xue, W., Zender, L., Miething, C. et al. 2007. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445:656.
60. Iannello, A., Thompson, T. W., Ardolino, M., Lowe, S. W. and Raulet, D. H. 2013. p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells. J. Exp. Med. 210:2057.
61. Quigley, D., Silwal-Pandit, L., Dannenfelser, R. et al. 2015. Lymphocyte Invasion in IC10/Basal-Like Breast Tumors Is Associated with Wild-Type TP53. Mol. Cancer Res. 13:493.
62. Bassères, D. S. and Baldwin, A. S. 2006. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 25:6817.
63. Baldwin, A. S. 2012. Regulation of cell death and autophagy by IKK and NF-kappaB: critical mechanisms in immune function and cancer. Immunol. Rev. 246:327.
64. Pikarsky, E., Porat, R. M., Stein, I. et al. 2004. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431:461.
65. Greten, F. R., Eckmann, L., Greten, T. F. et al. 2004. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118:285.
66. Muthuswamy, R., Berk, E., Junecko, B. F. et al. 2012. NF-κB hyperactivation in tumor tissues allows tumor-selective reprogramming of the chemokine microenvironment to enhance the recruitment of cytolytic T effector cells. Cancer Res. 72:3735.
67. Wang, T., Niu, G., Kortylewski, M. et al. 2004. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat. Med. 10:48.
68. Burdelya, L., Kujawski, M., Niu, G. et al. 2005. Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects. J. Immunol. 174:3925.
69. Toso, A., Revandkar, A., Di Mitri, D. et al. 2014. Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity. Cell Rep. 9:75.
70. Ihara, S., Kida, H., Arase, H. et al. 2012. Inhibitory roles of signal transducer and activator of transcription 3 in antitumor immunity during carcinogen-induced lung tumorigenesis. Cancer Res. 72:2990.
71. Pfirschke, C., Engblom, C., Rickelt, S. et al. 2016. Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. Immunity 44:343.
72. Liu, C., Peng, W., Xu, C. et al. 2013. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin. Cancer Res. 19:393.
73. Twyman-Saint Victor, C., Rech, A. J., Maity, A. et al. 2015. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520:373.